查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1698139

組織工程與再生市場－全球產業規模、佔有率、趨勢、機會與預測（按產品、應用、地區和競爭細分，2020-2030 年）

Tissue Engineering and Regeneration Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, by Application, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球組織工程與再生市場價值為 145.7 億美元，預計在預測期內將出現令人印象深刻的成長，到 2030 年的複合年成長率為 8.35%。組織工程與再生是生物醫學科學與工程領域，專注於開發生物替代品來修復或替換人體受損或患病的組織和器官。這些領域旨在恢復正常組織功能、促進癒合並改善各種疾病患者的生活品質。組織工程是利用細胞、生物材料和生化因素的組合來創造功能性和活的組織或器官的科學和實踐。

市場概覽
預測期 2026-2030
2024年市場規模 145.7億美元
2030年市場規模 233.9億美元
2025-2030 年複合年成長率 8.35%
成長最快的領域 組織工程
最大的市場 北美洲

關鍵市場促進因素

器官移植需求旺盛

主要市場挑戰

漫長而昂貴的開發過程

主要市場趨勢

個人化醫療

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球組織工程與再生市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依產品（生物材料、細胞療法、組織工程）
    • 按應用（骨科、皮膚科、心臟科、神經科、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：亞太組織工程與再生市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 澳洲
    • 日本
    • 韓國

第7章：歐洲組織工程與再生市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 西班牙
    • 義大利
    • 英國

第8章：北美組織工程與再生市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 墨西哥
    • 加拿大

第9章：南美洲組織工程與再生市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲組織工程與再生市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：全球組織工程與再生市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

  • Organogenesis Inc.
  • Acelity LP Inc
  • Zimmer Biomet Holdings Inc.
  • Stryker Corporation
  • Integra LifeSciences Holdings Corporation
  • Medtronic plc
  • Smith & Nephew plc
  • Athersys Inc.
  • Vericel Corporation
  • Osiris Therapeutics, Inc.

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 20609

Global Tissue Engineering and Regeneration Market was valued at USD 14.57 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.35% through 2030. Tissue Engineering and Regeneration are fields of biomedical science and engineering that focus on the development of biological substitutes to repair or replace damaged or diseased tissues and organs in the human body. These fields aim to restore normal tissue function, promote healing, and improve the quality of life for patients suffering from a wide range of medical conditions. Tissue engineering is the science and practice of creating functional and living tissues or organs using a combination of cells, biomaterials, and biochemical factors.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 14.57 Billion
Market Size 2030USD 23.39 Billion
CAGR 2025-20308.35%
Fastest Growing SegmentTissue Engineering
Largest MarketNorth America

Key Market Drivers

High Demand for Organ Transplants

The demand for organ transplants far exceeds the supply of available donor organs. This shortage of organs for transplantation has led to long waiting lists, and many patients may not receive a transplant in time. Tissue engineering offers a potential solution to address this organ shortage by creating lab-grown organs and tissues. Tissue engineering and regenerative medicine techniques involve growing functional organs and tissues in the laboratory using a patient's cells or other biocompatible materials. This approach provides an alternative source of organs for transplantation, reducing the dependence on donor organs. Tissue engineering allows for the creation of personalized organs that can be tailored to individual patients. This reduces the risk of organ rejection and the need for long-term immunosuppressive medications, which are necessary in traditional organ transplantation. Tissue engineering can create organs that are traditionally challenging to obtain from donors, such as vascularized organs, like hearts and kidneys. This expands the range of available organs for transplantation. In January 2023, a research team led by Dr. Hasan Erbil Abaci at Columbia University began developing techniques to create 3D-engineered skin customized for complex body parts. These tailored grafts can be transplanted with minimal suturing, improving surgical efficiency and outcomes.

Key Market Challenges

Long and Expensive Development Process

The development of regenerative therapies begins with extensive research and preclinical testing to understand the safety and efficacy of the proposed treatments. This stage can take many years and involve substantial financial resources. Clinical trials are a critical step in the development process to demonstrate the safety and effectiveness of regenerative therapies in humans. Conducting these trials involves a substantial investment, takes several years, and requires compliance with stringent regulatory requirements. Obtaining regulatory approvals from agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) is a lengthy and costly process. Companies must meet rigorous standards and provide comprehensive data to prove the safety and efficacy of their therapies. Transitioning from small-scale laboratory production to large-scale manufacturing can be challenging. Ensuring consistent and cost-effective production of regenerative therapies is a complex task. Maintaining quality control and standardization throughout the manufacturing process is crucial. Deviations can lead to product inconsistency and may pose risks to patient safety. The development of regenerative therapies requires substantial financial resources, including funding for research, clinical trials, manufacturing facilities, and regulatory compliance. Raising this capital can be a barrier to entry for startups and smaller companies. Many regenerative therapies do not successfully make it to market. The high failure rate in clinical trials and the lengthy timelines contribute to the overall cost of development. The long development process can result in market uncertainties. By the time a therapy reaches the market, changes in the competitive landscape or evolving clinical standards can impact its commercial success.

Key Market Trends

Personalized Medicine

Tissue engineering and regenerative medicine aim to create therapies that are customized to each patient's unique needs. This approach can address individual variations in health, genetics, and disease. Induced pluripotent stem cells (iPSCs) are reprogrammed from a patient's own cells and can be used to generate patient-specific tissues and organs. This minimizes the risk of immune rejection and graft-versus-host disease. Advancements in genomics and molecular profiling allow for a detailed analysis of a patient's genetic and molecular characteristics. This information is used to guide treatment decisions and tailor regenerative therapies. iPSCs and patient-derived cells are used to create disease models, enabling researchers to study diseases in a patient-specific context. This is valuable for understanding disease mechanisms and testing potential treatments. Personalized regenerative therapies reduce the risk of immune rejection, as they are based on the patient's own cells. This minimizes the need for immunosuppressive drugs. By understanding a patient's genetic and molecular profile, clinicians can optimize the choice of tissue engineering and regenerative therapies. This ensures that the treatment is more likely to be effective and safe for the individual patient. Personalized medicine allows clinicians to predict a patient's response to specific therapies, helping to select the most appropriate regenerative approach for a better outcome. Personalized medicine places the patient at the center of care, emphasizing tailored treatments that consider the patient's unique biology, preferences, and needs. In some cases, companion diagnostics are used to identify the most suitable regenerative therapy for a patient based on their genetic or molecular profile.

Key Market Players

  • Organogenesis Inc.
  • Acelity L.P. Inc.
  • Zimmer Biomet Holdings Inc.
  • Stryker Corporation
  • Integra LifeSciences Holdings Corporation
  • Medtronic plc
  • Smith & Nephew plc
  • Athersys Inc.
  • Vericel Corporation
  • Osiris Therapeutics, Inc.

Report Scope:

In this report, the Global Tissue Engineering and Regeneration Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tissue Engineering and Regeneration Market, By Product:

  • Biomaterials
  • Cell Therapy
  • Tissue Engineering

Tissue Engineering and Regeneration Market, By Application:

  • Orthopedics
  • Dermatology
  • Cardiology
  • Neurology
  • Others

Tissue Engineering and Regeneration Market, By region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Tissue Engineering and Regeneration Market.

Available Customizations:

Global Tissue Engineering and Regeneration Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tissue Engineering and Regeneration Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Biomaterials, Cell Therapy, Tissue Engineering)
    • 5.2.2. By Application (Orthopedics, Dermatology, Cardiology, Neurology, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Tissue Engineering and Regeneration Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Tissue Engineering and Regeneration Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. India Tissue Engineering and Regeneration Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Australia Tissue Engineering and Regeneration Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application
    • 6.3.4. Japan Tissue Engineering and Regeneration Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Product
        • 6.3.4.2.2. By Application
    • 6.3.5. South Korea Tissue Engineering and Regeneration Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Product
        • 6.3.5.2.2. By Application

7. Europe Tissue Engineering and Regeneration Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Tissue Engineering and Regeneration Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Tissue Engineering and Regeneration Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. Spain Tissue Engineering and Regeneration Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Tissue Engineering and Regeneration Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. United Kingdom Tissue Engineering and Regeneration Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. North America Tissue Engineering and Regeneration Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Tissue Engineering and Regeneration Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. Mexico Tissue Engineering and Regeneration Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. Canada Tissue Engineering and Regeneration Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application

9. South America Tissue Engineering and Regeneration Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Tissue Engineering and Regeneration Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Tissue Engineering and Regeneration Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Tissue Engineering and Regeneration Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. Middle East and Africa Tissue Engineering and Regeneration Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Tissue Engineering and Regeneration Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Tissue Engineering and Regeneration Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Tissue Engineering and Regeneration Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Tissue Engineering and Regeneration Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Organogenesis Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Acelity L.P. Inc
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Zimmer Biomet Holdings Inc.
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. Stryker Corporation
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Integra LifeSciences Holdings Corporation
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. Medtronic plc
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Smith & Nephew plc
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Athersys Inc.
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Vericel Corporation
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10.Osiris Therapeutics, Inc.
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer